和黃醫藥(00013.HK):授出認股權計劃項下的認股權及長期獎勵計劃項下的獎勵
格隆匯8月6日丨和黃醫藥(00013.HK)宣佈,其已於2024年8月5日授出和黃醫藥於2015年採納的認股權計劃("認股權計劃")項下的認股權及和黃醫藥於2015年採納的長期獎勵計劃("長期獎勵計劃")項下的獎勵。
和黃醫藥向蘇慰國(執行董事、首席執行官兼首席科學官)授出其認股權計劃項下的認股權,惟須受表現目標所規限;在承授人接納的前提下,以供認購公司股本中合共1,405,767股每股面值0.10美元的普通股。
和黃醫藥向其1名僱員授出其認股權計劃項下的認股權,在承授人接納的前提下,以供認購公司股本中合共200,000股普通股
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.